Prasugrel hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for prasugrel hydrochloride and what is the scope of freedom to operate?
Prasugrel hydrochloride
is the generic ingredient in three branded drugs marketed by Cosette, Accord Hlthcare, Amneal Pharms, Aurobindo Pharma, Chartwell Rx, Dr Reddys, Hec Pharm, Lupin Ltd, Mylan, Panacea, and Unichem, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.There are seventeen drug master file entries for prasugrel hydrochloride. Nine suppliers are listed for this compound.
Summary for prasugrel hydrochloride
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 11 |
NDAs: | 11 |
Drug Master File Entries: | 17 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Clinical Trials: | 226 |
Patent Applications: | 121 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for prasugrel hydrochloride |
What excipients (inactive ingredients) are in prasugrel hydrochloride? | prasugrel hydrochloride excipients list |
DailyMed Link: | prasugrel hydrochloride at DailyMed |
Recent Clinical Trials for prasugrel hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ferdinando Varbella | Phase 3 |
Azienda Ospedaliera Universitaria Policlinico "G. Martino" | Phase 3 |
Gianluca Di Bella | Phase 3 |
Pharmacology for prasugrel hydrochloride
Drug Class | P2Y12 Platelet Inhibitor |
Mechanism of Action | P2Y12 Receptor Antagonists |
Physiological Effect | Decreased Platelet Aggregation |
Medical Subject Heading (MeSH) Categories for prasugrel hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for prasugrel hydrochloride
Paragraph IV (Patent) Challenges for PRASUGREL HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
EFFIENT | Tablets | prasugrel hydrochloride | 5 mg and 10 mg | 022307 | 17 | 2013-07-10 |
US Patents and Regulatory Information for prasugrel hydrochloride
Expired US Patents for prasugrel hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cosette | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-001 | Jul 10, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Cosette | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-001 | Jul 10, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Cosette | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-002 | Jul 10, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Cosette | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-002 | Jul 10, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Cosette | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-002 | Jul 10, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Cosette | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-002 | Jul 10, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Cosette | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-001 | Jul 10, 2009 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for prasugrel hydrochloride
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Mylan Pharmaceuticals Limited | Prasugrel Mylan | prasugrel | EMEA/H/C/004644 Prasugrel Mylan, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). |
Authorised | yes | no | no | 2018-05-15 | |
Substipharm | Efient | prasugrel | EMEA/H/C/000984 Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). |
Authorised | no | no | no | 2009-02-24 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.